zonisamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2872 | 68291-97-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents, blocks sodium channels and reduces voltage-dependent, transient inward currents (T-type Ca2+ currents), consequently stabilizing neuronal membranes and suppressing neuronal hypersynchronization
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.80 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 22 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 40.39 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 27, 2000 | FDA | EISAI INC | |
| March 10, 2005 | EMA | ||
| Dec. 4, 2008 | PMDA | Dainippon Sumitomo Pharma Co., Ltd. |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Seizure | 857.13 | 15.46 | 457 | 12854 | 132177 | 63343534 |
| Multiple-drug resistance | 274.07 | 15.46 | 82 | 13229 | 5088 | 63470623 |
| Status epilepticus | 171.46 | 15.46 | 77 | 13234 | 15156 | 63460555 |
| Generalised tonic-clonic seizure | 156.14 | 15.46 | 89 | 13222 | 28927 | 63446784 |
| Drug reaction with eosinophilia and systemic symptoms | 153.69 | 15.46 | 93 | 13218 | 33743 | 63441968 |
| Epilepsy | 150.98 | 15.46 | 85 | 13226 | 26980 | 63448731 |
| Atonic seizures | 121.75 | 15.46 | 28 | 13283 | 611 | 63475100 |
| Irritability | 96.93 | 15.46 | 68 | 13243 | 31626 | 63444085 |
| Aggression | 90.05 | 15.46 | 58 | 13253 | 23440 | 63452271 |
| Drug ineffective | 84.98 | 15.46 | 436 | 12875 | 1044329 | 62431382 |
| Stevens-Johnson syndrome | 84.47 | 15.46 | 57 | 13254 | 24893 | 63450818 |
| Somnolence | 83.75 | 15.46 | 141 | 13170 | 178544 | 63297167 |
| Cognitive disorder | 74.33 | 15.46 | 74 | 13237 | 55741 | 63419970 |
| Partial seizures | 73.67 | 15.46 | 32 | 13279 | 5810 | 63469901 |
| Focal dyscognitive seizures | 72.10 | 15.46 | 26 | 13285 | 2895 | 63472816 |
| Product substitution issue | 67.57 | 15.46 | 42 | 13269 | 15954 | 63459757 |
| Petit mal epilepsy | 65.48 | 15.46 | 26 | 13285 | 3768 | 63471943 |
| Drug eruption | 64.10 | 15.46 | 51 | 13260 | 28643 | 63447068 |
| Ataxia | 61.92 | 15.46 | 39 | 13272 | 15156 | 63460555 |
| Psychotic disorder | 60.23 | 15.46 | 47 | 13264 | 25665 | 63450046 |
| Suicidal behaviour | 59.60 | 15.46 | 22 | 13289 | 2617 | 63473094 |
| Drug withdrawal convulsions | 56.08 | 15.46 | 18 | 13293 | 1407 | 63474304 |
| Choroidal effusion | 55.32 | 15.46 | 14 | 13297 | 462 | 63475249 |
| Dyskinesia | 55.20 | 15.46 | 49 | 13262 | 31953 | 63443758 |
| Therapeutic response unexpected | 54.45 | 15.46 | 39 | 13272 | 18720 | 63456991 |
| Vestibular migraine | 54.00 | 15.46 | 12 | 13299 | 223 | 63475488 |
| Drug resistance | 47.49 | 15.46 | 39 | 13272 | 22894 | 63452817 |
| Tonic convulsion | 45.43 | 15.46 | 15 | 13296 | 1282 | 63474429 |
| Infantile spasms | 44.07 | 15.46 | 10 | 13301 | 205 | 63475506 |
| Hyperammonaemic encephalopathy | 43.12 | 15.46 | 17 | 13294 | 2417 | 63473294 |
| Drug interaction | 42.80 | 15.46 | 125 | 13186 | 229006 | 63246705 |
| Change in seizure presentation | 42.12 | 15.46 | 11 | 13300 | 412 | 63475299 |
| Depression | 41.40 | 15.46 | 112 | 13199 | 196380 | 63279331 |
| Ovarian granulosa-theca cell tumour | 41.24 | 15.46 | 7 | 13304 | 27 | 63475684 |
| Joint swelling | 39.56 | 15.46 | 10 | 13301 | 327656 | 63148055 |
| Epilepsy with myoclonic-atonic seizures | 38.60 | 15.46 | 8 | 13303 | 105 | 63475606 |
| Myoclonic epilepsy | 34.12 | 15.46 | 12 | 13299 | 1242 | 63474469 |
| Bipolar disorder | 33.86 | 15.46 | 21 | 13290 | 7939 | 63467772 |
| Epileptic psychosis | 33.16 | 15.46 | 6 | 13305 | 36 | 63475675 |
| Toxic epidermal necrolysis | 32.62 | 15.46 | 33 | 13278 | 25301 | 63450410 |
| Diplopia | 32.57 | 15.46 | 32 | 13279 | 23696 | 63452015 |
| Hallucination, visual | 32.19 | 15.46 | 29 | 13282 | 19269 | 63456442 |
| Rheumatoid arthritis | 32.10 | 15.46 | 7 | 13304 | 253812 | 63221899 |
| Arthralgia | 31.72 | 15.46 | 44 | 13267 | 569666 | 62906045 |
| Oculomucocutaneous syndrome | 31.71 | 15.46 | 7 | 13304 | 126 | 63475585 |
| Abortion spontaneous | 31.59 | 15.46 | 44 | 13267 | 47151 | 63428560 |
| Suicidal ideation | 31.51 | 15.46 | 51 | 13260 | 62370 | 63413341 |
| Brown tumour | 31.43 | 15.46 | 6 | 13305 | 50 | 63475661 |
| Arthropathy | 30.67 | 15.46 | 6 | 13305 | 234786 | 63240925 |
| Placental infarction | 30.44 | 15.46 | 8 | 13303 | 307 | 63475404 |
| Systemic lupus erythematosus | 30.29 | 15.46 | 4 | 13307 | 208914 | 63266797 |
| Retinogram abnormal | 29.96 | 15.46 | 7 | 13304 | 164 | 63475547 |
| Agitation | 29.05 | 15.46 | 48 | 13263 | 59709 | 63416002 |
| Herpes oesophagitis | 28.59 | 15.46 | 7 | 13304 | 201 | 63475510 |
| Swelling | 28.58 | 15.46 | 11 | 13300 | 275367 | 63200344 |
| Therapeutic response changed | 28.43 | 15.46 | 10 | 13301 | 1035 | 63474676 |
| Mood altered | 28.30 | 15.46 | 24 | 13287 | 14719 | 63460992 |
| Therapeutic product effective for unapproved indication | 27.84 | 15.46 | 6 | 13305 | 96 | 63475615 |
| Abnormal behaviour | 27.75 | 15.46 | 28 | 13283 | 21398 | 63454313 |
| Diarrhoea | 27.66 | 15.46 | 69 | 13242 | 715297 | 62760414 |
| Intentional overdose | 27.60 | 15.46 | 53 | 13258 | 74099 | 63401612 |
| Hepatic function abnormal | 26.94 | 15.46 | 36 | 13275 | 37106 | 63438605 |
| Lichen planus | 26.87 | 15.46 | 12 | 13299 | 2326 | 63473385 |
| Infusion related reaction | 26.85 | 15.46 | 9 | 13302 | 245512 | 63230199 |
| Depressed mood | 26.20 | 15.46 | 37 | 13274 | 40154 | 63435557 |
| Dyspnoea | 26.17 | 15.46 | 63 | 13248 | 661250 | 62814461 |
| Calculus urinary | 25.69 | 15.46 | 10 | 13301 | 1374 | 63474337 |
| Anger | 25.40 | 15.46 | 21 | 13290 | 12435 | 63463276 |
| Magnetic resonance imaging head abnormal | 25.29 | 15.46 | 11 | 13300 | 2002 | 63473709 |
| Encapsulating peritoneal sclerosis | 24.98 | 15.46 | 7 | 13304 | 343 | 63475368 |
| Myoclonus | 24.81 | 15.46 | 23 | 13288 | 15845 | 63459866 |
| Anticonvulsant drug level increased | 24.80 | 15.46 | 10 | 13301 | 1507 | 63474204 |
| Disturbance in attention | 24.66 | 15.46 | 35 | 13276 | 38154 | 63437557 |
| Exposure during pregnancy | 24.49 | 15.46 | 80 | 13231 | 155467 | 63320244 |
| Pneumonia aspiration | 24.32 | 15.46 | 33 | 13278 | 34507 | 63441204 |
| Migraine | 23.87 | 15.46 | 61 | 13250 | 103285 | 63372426 |
| Withdrawal syndrome | 23.85 | 15.46 | 25 | 13286 | 19972 | 63455739 |
| Renal tubular acidosis | 23.75 | 15.46 | 10 | 13301 | 1682 | 63474029 |
| Severe myoclonic epilepsy of infancy | 23.70 | 15.46 | 5 | 13306 | 72 | 63475639 |
| Suicide attempt | 23.23 | 15.46 | 44 | 13267 | 60874 | 63414837 |
| Endometrial cancer | 23.20 | 15.46 | 12 | 13299 | 3213 | 63472498 |
| Therapeutic product ineffective for unapproved indication | 23.10 | 15.46 | 6 | 13305 | 220 | 63475491 |
| Upper respiratory tract inflammation | 22.92 | 15.46 | 11 | 13300 | 2512 | 63473199 |
| Hallucination, auditory | 22.83 | 15.46 | 20 | 13291 | 12804 | 63462907 |
| Coma | 22.73 | 15.46 | 45 | 13266 | 64319 | 63411392 |
| Altered state of consciousness | 22.32 | 15.46 | 27 | 13284 | 25203 | 63450508 |
| Delusion | 21.92 | 15.46 | 19 | 13292 | 11998 | 63463713 |
| Neuroleptic malignant syndrome | 21.86 | 15.46 | 19 | 13292 | 12037 | 63463674 |
| Microcephaly | 21.83 | 15.46 | 8 | 13303 | 932 | 63474779 |
| Stress cardiomyopathy | 21.53 | 15.46 | 17 | 13294 | 9433 | 63466278 |
| Placental disorder | 21.48 | 15.46 | 9 | 13302 | 1495 | 63474216 |
| Hallucination | 21.41 | 15.46 | 40 | 13271 | 54777 | 63420934 |
| Depressed level of consciousness | 20.25 | 15.46 | 42 | 13269 | 62036 | 63413675 |
| Pain | 19.86 | 15.46 | 84 | 13227 | 740544 | 62735167 |
| Anticonvulsant drug level decreased | 19.60 | 15.46 | 8 | 13303 | 1244 | 63474467 |
| Aphasia | 19.50 | 15.46 | 29 | 13282 | 32971 | 63442740 |
| Immunoglobulins decreased | 19.36 | 15.46 | 8 | 13303 | 1284 | 63474427 |
| Product complaint | 18.94 | 15.46 | 18 | 13293 | 12791 | 63462920 |
| Abdominal discomfort | 18.61 | 15.46 | 24 | 13287 | 320861 | 63154850 |
| Sinus arrhythmia | 18.35 | 15.46 | 8 | 13303 | 1465 | 63474246 |
| Restless legs syndrome | 18.33 | 15.46 | 21 | 13290 | 18510 | 63457201 |
| Developmental delay | 18.29 | 15.46 | 8 | 13303 | 1475 | 63474236 |
| Tremor | 18.16 | 15.46 | 65 | 13246 | 132174 | 63343537 |
| Insomnia | 18.03 | 15.46 | 91 | 13220 | 215161 | 63260550 |
| Drug level increased | 17.98 | 15.46 | 23 | 13288 | 22713 | 63452998 |
| Dysmetria | 17.97 | 15.46 | 6 | 13305 | 531 | 63475180 |
| Myopia | 17.45 | 15.46 | 8 | 13303 | 1647 | 63474064 |
| Overdose | 17.04 | 15.46 | 58 | 13253 | 115020 | 63360691 |
| Discomfort | 16.84 | 15.46 | 7 | 13304 | 167367 | 63308344 |
| Human herpes virus 6 serology positive | 16.83 | 15.46 | 4 | 13307 | 101 | 63475610 |
| Gestational diabetes | 16.80 | 15.46 | 14 | 13297 | 8382 | 63467329 |
| Sudden unexplained death in epilepsy | 16.58 | 15.46 | 5 | 13306 | 318 | 63475393 |
| Hypothermia | 16.23 | 15.46 | 17 | 13294 | 13564 | 63462147 |
| Electrocardiogram PR prolongation | 16.22 | 15.46 | 6 | 13305 | 718 | 63474993 |
| Ureterolithiasis | 16.19 | 15.46 | 8 | 13303 | 1944 | 63473767 |
| Hypertension | 16.08 | 15.46 | 21 | 13290 | 279282 | 63196429 |
| Affective disorder | 16.07 | 15.46 | 12 | 13299 | 6134 | 63469577 |
| Abdominal pain | 15.95 | 15.46 | 23 | 13288 | 293433 | 63182278 |
| Nystagmus | 15.94 | 15.46 | 12 | 13299 | 6208 | 63469503 |
| Encephalocele | 15.63 | 15.46 | 4 | 13307 | 138 | 63475573 |
| Illiteracy | 15.51 | 15.46 | 3 | 13308 | 27 | 63475684 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Seizure | 533.99 | 17.99 | 332 | 8650 | 104525 | 34843424 |
| Status epilepticus | 281.58 | 17.99 | 110 | 8872 | 12504 | 34935445 |
| Multiple-drug resistance | 161.79 | 17.99 | 58 | 8924 | 5181 | 34942768 |
| Drug ineffective | 132.16 | 17.99 | 331 | 8651 | 456420 | 34491529 |
| Generalised tonic-clonic seizure | 130.12 | 17.99 | 76 | 8906 | 21098 | 34926851 |
| Somnolence | 118.31 | 17.99 | 144 | 8838 | 110972 | 34836977 |
| Partial seizures | 104.31 | 17.99 | 41 | 8941 | 4719 | 34943230 |
| Aggression | 98.64 | 17.99 | 81 | 8901 | 38883 | 34909066 |
| Epilepsy | 93.63 | 17.99 | 62 | 8920 | 21433 | 34926516 |
| Ataxia | 70.29 | 17.99 | 44 | 8938 | 13809 | 34934140 |
| Neonatal pneumonia | 64.09 | 17.99 | 13 | 8969 | 122 | 34947827 |
| Drug reaction with eosinophilia and systemic symptoms | 62.12 | 17.99 | 58 | 8924 | 32954 | 34914995 |
| Neonatal hypotension | 61.72 | 17.99 | 13 | 8969 | 149 | 34947800 |
| Nystagmus | 61.18 | 17.99 | 28 | 8954 | 4687 | 34943262 |
| Stevens-Johnson syndrome | 60.69 | 17.99 | 45 | 8937 | 18594 | 34929355 |
| Choroidal effusion | 59.46 | 17.99 | 13 | 8969 | 180 | 34947769 |
| Postictal psychosis | 58.67 | 17.99 | 13 | 8969 | 192 | 34947757 |
| Focal dyscognitive seizures | 57.00 | 17.99 | 19 | 8963 | 1362 | 34946587 |
| Hyperammonaemic encephalopathy | 54.38 | 17.99 | 21 | 8961 | 2303 | 34945646 |
| Pneumonia aspiration | 53.98 | 17.99 | 60 | 8922 | 41843 | 34906106 |
| Dyspnoea | 52.38 | 17.99 | 16 | 8966 | 376766 | 34571183 |
| Developmental delay | 50.77 | 17.99 | 21 | 8961 | 2754 | 34945195 |
| Irritability | 49.59 | 17.99 | 45 | 8937 | 24645 | 34923304 |
| Altered state of consciousness | 46.52 | 17.99 | 42 | 8940 | 22851 | 34925098 |
| Calculus urinary | 45.02 | 17.99 | 16 | 8966 | 1391 | 34946558 |
| Psychotic disorder | 44.15 | 17.99 | 42 | 8940 | 24410 | 34923539 |
| Petit mal epilepsy | 42.21 | 17.99 | 19 | 8963 | 3059 | 34944890 |
| Abnormal behaviour | 41.53 | 17.99 | 41 | 8941 | 24928 | 34923021 |
| Vitamin D deficiency | 41.29 | 17.99 | 24 | 8958 | 6584 | 34941365 |
| Product substitution issue | 41.24 | 17.99 | 28 | 8954 | 10067 | 34937882 |
| Toxic epidermal necrolysis | 36.85 | 17.99 | 36 | 8946 | 21610 | 34926339 |
| Nephrolithiasis | 36.60 | 17.99 | 42 | 8940 | 30291 | 34917658 |
| Encephalopathy | 36.20 | 17.99 | 45 | 8937 | 35274 | 34912675 |
| Tonic convulsion | 35.95 | 17.99 | 13 | 8969 | 1188 | 34946761 |
| Delusion | 35.61 | 17.99 | 28 | 8954 | 12607 | 34935342 |
| Respiratory disorder neonatal | 35.56 | 17.99 | 14 | 8968 | 1616 | 34946333 |
| Fanconi syndrome | 34.83 | 17.99 | 14 | 8968 | 1706 | 34946243 |
| Sudden unexplained death in epilepsy | 34.12 | 17.99 | 10 | 8972 | 468 | 34947481 |
| Dyskinesia | 33.97 | 17.99 | 35 | 8947 | 22378 | 34925571 |
| Salivary hypersecretion | 33.01 | 17.99 | 23 | 8959 | 8621 | 34939328 |
| Drug withdrawal convulsions | 32.48 | 17.99 | 12 | 8970 | 1165 | 34946784 |
| Myoclonus | 29.87 | 17.99 | 27 | 8955 | 14698 | 34933251 |
| Myoclonic epilepsy | 29.02 | 17.99 | 11 | 8971 | 1146 | 34946803 |
| Condition aggravated | 28.50 | 17.99 | 111 | 8871 | 192085 | 34755864 |
| Drug eruption | 28.23 | 17.99 | 30 | 8952 | 19868 | 34928081 |
| Cytotoxic oedema | 28.15 | 17.99 | 7 | 8975 | 174 | 34947775 |
| Temporal lobe epilepsy | 28.03 | 17.99 | 7 | 8975 | 177 | 34947772 |
| Drug interaction | 26.89 | 17.99 | 122 | 8860 | 225824 | 34722125 |
| Lymphocyte stimulation test positive | 26.15 | 17.99 | 9 | 8973 | 711 | 34947238 |
| Anticonvulsant drug level increased | 25.47 | 17.99 | 11 | 8971 | 1605 | 34946344 |
| Atonic seizures | 25.32 | 17.99 | 7 | 8975 | 265 | 34947684 |
| Premature baby | 25.06 | 17.99 | 28 | 8954 | 19605 | 34928344 |
| Retinogram abnormal | 25.05 | 17.99 | 6 | 8976 | 127 | 34947822 |
| Parkinsonism | 25.04 | 17.99 | 19 | 8963 | 8119 | 34939830 |
| Foetal exposure during pregnancy | 24.74 | 17.99 | 39 | 8943 | 38062 | 34909887 |
| Arthralgia | 23.95 | 17.99 | 7 | 8975 | 170034 | 34777915 |
| Small for dates baby | 23.84 | 17.99 | 14 | 8968 | 3913 | 34944036 |
| Hallucination | 23.37 | 17.99 | 45 | 8937 | 51453 | 34896496 |
| Congenital inguinal hernia | 23.11 | 17.99 | 6 | 8976 | 178 | 34947771 |
| Wrong schedule | 23.11 | 17.99 | 6 | 8976 | 178 | 34947771 |
| Death | 23.10 | 17.99 | 42 | 8940 | 398007 | 34549942 |
| Hepatic function abnormal | 22.93 | 17.99 | 41 | 8941 | 44322 | 34903627 |
| Congenital cutis laxa | 22.68 | 17.99 | 5 | 8977 | 72 | 34947877 |
| Infantile spasms | 22.32 | 17.99 | 6 | 8976 | 204 | 34947745 |
| Tachyarrhythmia | 22.26 | 17.99 | 13 | 8969 | 3595 | 34944354 |
| Aminoaciduria | 20.41 | 17.99 | 6 | 8976 | 284 | 34947665 |
| Drug resistance | 20.35 | 17.99 | 29 | 8953 | 25898 | 34922051 |
| Product lot number issue | 20.18 | 17.99 | 4 | 8978 | 33 | 34947916 |
| Angle closure glaucoma | 20.11 | 17.99 | 8 | 8974 | 949 | 34947000 |
| Implant site pruritus | 19.72 | 17.99 | 3 | 8979 | 3 | 34947946 |
| Partial seizures with secondary generalisation | 19.54 | 17.99 | 6 | 8976 | 330 | 34947619 |
| Aura | 19.43 | 17.99 | 6 | 8976 | 336 | 34947613 |
| Language disorder | 19.06 | 17.99 | 10 | 8972 | 2246 | 34945703 |
| Idiopathic generalised epilepsy | 18.90 | 17.99 | 4 | 8978 | 47 | 34947902 |
| Hallucination, visual | 18.75 | 17.99 | 23 | 8959 | 17768 | 34930181 |
| Febrile neutropenia | 18.60 | 17.99 | 6 | 8976 | 136843 | 34811106 |
| Implant site rash | 18.51 | 17.99 | 3 | 8979 | 6 | 34947943 |
| Assisted delivery | 18.51 | 17.99 | 3 | 8979 | 6 | 34947943 |
| Oculomucocutaneous syndrome | 18.49 | 17.99 | 5 | 8977 | 174 | 34947775 |
| Electroencephalogram abnormal | 18.18 | 17.99 | 10 | 8972 | 2468 | 34945481 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Seizure | 766.49 | 15.40 | 490 | 17054 | 188344 | 79538500 |
| Status epilepticus | 375.09 | 15.40 | 157 | 17387 | 24884 | 79701960 |
| Multiple-drug resistance | 316.45 | 15.40 | 105 | 17439 | 8703 | 79718141 |
| Generalised tonic-clonic seizure | 212.81 | 15.40 | 128 | 17416 | 43782 | 79683062 |
| Epilepsy | 208.15 | 15.40 | 123 | 17421 | 40737 | 79686107 |
| Drug reaction with eosinophilia and systemic symptoms | 204.88 | 15.40 | 144 | 17400 | 64100 | 79662744 |
| Drug ineffective | 179.24 | 15.40 | 581 | 16963 | 1080332 | 78646512 |
| Somnolence | 164.40 | 15.40 | 231 | 17313 | 238750 | 79488094 |
| Aggression | 161.91 | 15.40 | 114 | 17430 | 50844 | 79676000 |
| Partial seizures | 143.48 | 15.40 | 59 | 17485 | 8919 | 79717925 |
| Stevens-Johnson syndrome | 127.61 | 15.40 | 89 | 17455 | 39077 | 79687767 |
| Choroidal effusion | 113.57 | 15.40 | 27 | 17517 | 650 | 79726194 |
| Irritability | 112.35 | 15.40 | 84 | 17460 | 41060 | 79685784 |
| Ataxia | 106.01 | 15.40 | 67 | 17477 | 24972 | 79701872 |
| Focal dyscognitive seizures | 103.10 | 15.40 | 36 | 17508 | 3476 | 79723368 |
| Petit mal epilepsy | 96.17 | 15.40 | 39 | 17505 | 5688 | 79721156 |
| Psychotic disorder | 94.47 | 15.40 | 76 | 17468 | 41326 | 79685518 |
| Atonic seizures | 89.93 | 15.40 | 23 | 17521 | 754 | 79726090 |
| Dyskinesia | 87.22 | 15.40 | 75 | 17469 | 44698 | 79682146 |
| Hyperammonaemic encephalopathy | 81.79 | 15.40 | 33 | 17511 | 4749 | 79722095 |
| Tonic convulsion | 77.85 | 15.40 | 26 | 17518 | 2194 | 79724650 |
| Pneumonia aspiration | 77.09 | 15.40 | 84 | 17460 | 66883 | 79659961 |
| Drug eruption | 72.48 | 15.40 | 67 | 17477 | 43868 | 79682976 |
| Drug interaction | 70.60 | 15.40 | 226 | 17318 | 414957 | 79311887 |
| Nystagmus | 67.18 | 15.40 | 36 | 17508 | 9868 | 79716976 |
| Drug resistance | 65.08 | 15.40 | 62 | 17482 | 42151 | 79684693 |
| Altered state of consciousness | 63.11 | 15.40 | 62 | 17482 | 43760 | 79683084 |
| Postictal psychosis | 62.88 | 15.40 | 13 | 17531 | 160 | 79726684 |
| Dyspnoea | 62.66 | 15.40 | 58 | 17486 | 856967 | 78869877 |
| Toxic epidermal necrolysis | 60.37 | 15.40 | 61 | 17483 | 44520 | 79682324 |
| Calculus urinary | 60.06 | 15.40 | 22 | 17522 | 2438 | 79724406 |
| Cognitive disorder | 59.30 | 15.40 | 75 | 17469 | 69851 | 79656993 |
| Delusion | 58.66 | 15.40 | 43 | 17501 | 20380 | 79706464 |
| Drug withdrawal convulsions | 54.75 | 15.40 | 20 | 17524 | 2200 | 79724644 |
| Retinogram abnormal | 53.65 | 15.40 | 13 | 17531 | 340 | 79726504 |
| Myoclonic epilepsy | 53.27 | 15.40 | 19 | 17525 | 1951 | 79724893 |
| Hepatic function abnormal | 52.09 | 15.40 | 72 | 17472 | 73035 | 79653809 |
| Suicidal behaviour | 50.73 | 15.40 | 21 | 17523 | 3226 | 79723618 |
| Abnormal behaviour | 47.79 | 15.40 | 49 | 17495 | 36372 | 79690472 |
| Hallucination, visual | 46.55 | 15.40 | 46 | 17498 | 32683 | 79694161 |
| Arthralgia | 46.26 | 15.40 | 35 | 17509 | 571768 | 79155076 |
| Myoclonus | 45.26 | 15.40 | 42 | 17502 | 27618 | 79699226 |
| Change in seizure presentation | 43.91 | 15.40 | 12 | 17532 | 510 | 79726334 |
| Fanconi syndrome | 43.03 | 15.40 | 18 | 17526 | 2838 | 79724006 |
| Lymphocyte stimulation test positive | 42.65 | 15.40 | 14 | 17530 | 1119 | 79725725 |
| Ovarian granulosa-theca cell tumour | 41.55 | 15.40 | 7 | 17537 | 24 | 79726820 |
| Neonatal pneumonia | 40.12 | 15.40 | 7 | 17537 | 31 | 79726813 |
| Neonatal hypotension | 39.94 | 15.40 | 7 | 17537 | 32 | 79726812 |
| Joint swelling | 39.02 | 15.40 | 8 | 17536 | 288638 | 79438206 |
| Salivary hypersecretion | 38.72 | 15.40 | 29 | 17515 | 14195 | 79712649 |
| Vitamin D deficiency | 38.62 | 15.40 | 29 | 17515 | 14250 | 79712594 |
| Epilepsy with myoclonic-atonic seizures | 38.01 | 15.40 | 8 | 17536 | 108 | 79726736 |
| Anticonvulsant drug level increased | 37.57 | 15.40 | 16 | 17528 | 2637 | 79724207 |
| Nephrolithiasis | 37.23 | 15.40 | 52 | 17492 | 53239 | 79673605 |
| Placental infarction | 37.10 | 15.40 | 8 | 17536 | 122 | 79726722 |
| Hallucination | 36.85 | 15.40 | 67 | 17477 | 85678 | 79641166 |
| Respiratory disorder neonatal | 36.05 | 15.40 | 7 | 17537 | 61 | 79726783 |
| Infantile spasms | 35.67 | 15.40 | 9 | 17535 | 279 | 79726565 |
| Oculomucocutaneous syndrome | 34.22 | 15.40 | 9 | 17535 | 330 | 79726514 |
| Upper respiratory tract inflammation | 34.09 | 15.40 | 17 | 17527 | 4018 | 79722826 |
| Product substitution issue | 33.61 | 15.40 | 31 | 17513 | 20225 | 79706619 |
| Angle closure glaucoma | 32.63 | 15.40 | 15 | 17529 | 2961 | 79723883 |
| Neuroleptic malignant syndrome | 32.45 | 15.40 | 35 | 17509 | 27524 | 79699320 |
| Sudden unexplained death in epilepsy | 32.35 | 15.40 | 10 | 17534 | 658 | 79726186 |
| Encephalopathy | 31.97 | 15.40 | 55 | 17489 | 67342 | 79659502 |
| Temporal lobe epilepsy | 31.77 | 15.40 | 9 | 17535 | 437 | 79726407 |
| Brown tumour | 30.83 | 15.40 | 6 | 17538 | 53 | 79726791 |
| Magnetic resonance imaging head abnormal | 30.71 | 15.40 | 14 | 17530 | 2712 | 79724132 |
| Diplopia | 30.12 | 15.40 | 37 | 17507 | 33429 | 79693415 |
| Vestibular migraine | 30.09 | 15.40 | 7 | 17537 | 153 | 79726691 |
| Febrile neutropenia | 30.00 | 15.40 | 7 | 17537 | 230992 | 79495852 |
| Swelling | 29.29 | 15.40 | 6 | 17538 | 216705 | 79510139 |
| Partial seizures with secondary generalisation | 28.55 | 15.40 | 9 | 17535 | 632 | 79726212 |
| Infusion related reaction | 27.94 | 15.40 | 8 | 17536 | 230229 | 79496615 |
| Therapeutic product effective for unapproved indication | 26.79 | 15.40 | 6 | 17538 | 110 | 79726734 |
| Mood swings | 26.54 | 15.40 | 27 | 17517 | 19853 | 79706991 |
| Developmental delay | 26.36 | 15.40 | 10 | 17534 | 1221 | 79725623 |
| Bronchial hyperreactivity | 26.25 | 15.40 | 13 | 17531 | 3027 | 79723817 |
| Disturbance in attention | 26.14 | 15.40 | 43 | 17501 | 50758 | 79676086 |
| Suicidal ideation | 25.90 | 15.40 | 54 | 17490 | 76286 | 79650558 |
| Depression | 25.65 | 15.40 | 105 | 17439 | 216685 | 79510159 |
| Hallucination, auditory | 25.63 | 15.40 | 27 | 17517 | 20666 | 79706178 |
| Placental disorder | 25.23 | 15.40 | 9 | 17535 | 924 | 79725920 |
| Anticonvulsant drug level decreased | 25.21 | 15.40 | 11 | 17533 | 1923 | 79724921 |
| Parkinsonism | 24.87 | 15.40 | 24 | 17520 | 16560 | 79710284 |
| Therapeutic response unexpected | 24.66 | 15.40 | 26 | 17518 | 19920 | 79706924 |
| Hyperammonaemia | 24.52 | 15.40 | 20 | 17524 | 11073 | 79715771 |
| Breast disorder | 24.43 | 15.40 | 11 | 17533 | 2070 | 79724774 |
| Agitation | 24.40 | 15.40 | 62 | 17482 | 99653 | 79627191 |
| Cytotoxic oedema | 23.78 | 15.40 | 7 | 17537 | 390 | 79726454 |
| Herpes oesophagitis | 23.74 | 15.40 | 7 | 17537 | 392 | 79726452 |
| Arthropathy | 23.73 | 15.40 | 5 | 17539 | 177106 | 79549738 |
| Therapeutic product ineffective for unapproved indication | 23.51 | 15.40 | 6 | 17538 | 195 | 79726649 |
| Human herpes virus 6 serology positive | 23.05 | 15.40 | 6 | 17538 | 211 | 79726633 |
| Small for dates baby | 22.52 | 15.40 | 7 | 17537 | 469 | 79726375 |
| Overdose | 22.40 | 15.40 | 90 | 17454 | 184116 | 79542728 |
| Diarrhoea | 22.24 | 15.40 | 109 | 17435 | 880380 | 78846464 |
| Therapeutic response shortened | 22.01 | 15.40 | 22 | 17522 | 15841 | 79711003 |
| Human herpesvirus 6 infection reactivation | 21.22 | 15.40 | 7 | 17537 | 568 | 79726276 |
| Peripheral swelling | 21.12 | 15.40 | 17 | 17527 | 269600 | 79457244 |
| Low birth weight baby | 20.67 | 15.40 | 7 | 17537 | 616 | 79726228 |
| Ureterolithiasis | 20.67 | 15.40 | 12 | 17532 | 3836 | 79723008 |
| Jealous delusion | 20.56 | 15.40 | 6 | 17538 | 324 | 79726520 |
| Depressed level of consciousness | 20.51 | 15.40 | 57 | 17487 | 96595 | 79630249 |
| Dysmetria | 20.44 | 15.40 | 8 | 17536 | 1063 | 79725781 |
| Illiteracy | 20.39 | 15.40 | 4 | 17540 | 37 | 79726807 |
| Abdominal pain | 20.35 | 15.40 | 34 | 17510 | 389535 | 79337309 |
| Speech disorder | 20.23 | 15.40 | 40 | 17504 | 54405 | 79672439 |
| Cough | 20.11 | 15.40 | 31 | 17513 | 366758 | 79360086 |
| Developmental regression | 19.93 | 15.40 | 4 | 17540 | 42 | 79726802 |
| Wrong schedule | 19.90 | 15.40 | 6 | 17538 | 363 | 79726481 |
| Mood altered | 19.85 | 15.40 | 22 | 17522 | 17825 | 79709019 |
| Gestational diabetes | 19.78 | 15.40 | 14 | 17530 | 6279 | 79720565 |
| Encephalocele | 19.68 | 15.40 | 4 | 17540 | 45 | 79726799 |
| Aminoaciduria | 19.51 | 15.40 | 6 | 17538 | 388 | 79726456 |
| Malaise | 19.47 | 15.40 | 50 | 17494 | 489819 | 79237025 |
| Electroencephalogram abnormal | 19.22 | 15.40 | 13 | 17531 | 5421 | 79721423 |
| Brain neoplasm | 18.77 | 15.40 | 13 | 17531 | 5633 | 79721211 |
| Lower respiratory tract infection | 18.70 | 15.40 | 3 | 17541 | 129217 | 79597627 |
| Haemoglobin decreased | 18.69 | 15.40 | 13 | 17531 | 222106 | 79504738 |
| Idiopathic generalised epilepsy | 18.67 | 15.40 | 4 | 17540 | 59 | 79726785 |
| Condition aggravated | 18.63 | 15.40 | 180 | 17364 | 500944 | 79225900 |
| Encapsulating peritoneal sclerosis | 18.54 | 15.40 | 7 | 17537 | 844 | 79726000 |
| Lichen planus | 18.52 | 15.40 | 10 | 17534 | 2781 | 79724063 |
| Stress cardiomyopathy | 18.35 | 15.40 | 17 | 17527 | 11149 | 79715695 |
| Hypotonia | 18.13 | 15.40 | 18 | 17526 | 12852 | 79713992 |
| Persecutory delusion | 17.98 | 15.40 | 12 | 17532 | 4897 | 79721947 |
| Osteomalacia | 17.94 | 15.40 | 8 | 17536 | 1472 | 79725372 |
| Personality change | 17.72 | 15.40 | 16 | 17528 | 10154 | 79716690 |
| Immunoglobulins decreased | 17.54 | 15.40 | 8 | 17536 | 1552 | 79725292 |
| Behaviour disorder | 17.47 | 15.40 | 13 | 17531 | 6300 | 79720544 |
| Atrial fibrillation | 17.43 | 15.40 | 11 | 17533 | 197875 | 79528969 |
| Electrocardiogram PR prolongation | 17.42 | 15.40 | 8 | 17536 | 1575 | 79725269 |
| Hypertension | 17.17 | 15.40 | 29 | 17515 | 330963 | 79395881 |
| Torticollis | 17.10 | 15.40 | 9 | 17535 | 2378 | 79724466 |
| Neutropenia | 17.06 | 15.40 | 23 | 17521 | 287687 | 79439157 |
| Drug level increased | 17.05 | 15.40 | 31 | 17513 | 39620 | 79687224 |
| Human herpesvirus 6 infection | 17.00 | 15.40 | 12 | 17532 | 5358 | 79721486 |
| Aphasia | 16.96 | 15.40 | 34 | 17510 | 46698 | 79680146 |
| Akinesia | 16.92 | 15.40 | 10 | 17534 | 3302 | 79723542 |
| Tremor | 16.76 | 15.40 | 78 | 17466 | 170005 | 79556839 |
| Pain | 16.68 | 15.40 | 89 | 17455 | 703713 | 79023131 |
| Impulse-control disorder | 16.55 | 15.40 | 8 | 17536 | 1766 | 79725078 |
| Cerebellar atrophy | 16.43 | 15.40 | 7 | 17537 | 1154 | 79725690 |
| Insomnia | 16.36 | 15.40 | 101 | 17443 | 245069 | 79481775 |
| Affective disorder | 16.32 | 15.40 | 14 | 17530 | 8305 | 79718539 |
| Coma | 16.31 | 15.40 | 54 | 17490 | 100595 | 79626249 |
| Staring | 16.23 | 15.40 | 9 | 17535 | 2636 | 79724208 |
| Renal tubular acidosis | 16.12 | 15.40 | 10 | 17534 | 3604 | 79723240 |
| Dyscalculia | 16.11 | 15.40 | 4 | 17540 | 116 | 79726728 |
| Anaemia | 15.76 | 15.40 | 48 | 17496 | 444967 | 79281877 |
| Suicide attempt | 15.74 | 15.40 | 47 | 17497 | 82885 | 79643959 |
| Stoma site extravasation | 15.74 | 15.40 | 5 | 17539 | 360 | 79726484 |
| Intentional product use issue | 15.53 | 15.40 | 7 | 17537 | 152105 | 79574739 |
| Dysarthria | 15.46 | 15.40 | 41 | 17503 | 67581 | 79659263 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N03AX15 | NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Other antiepileptics |
| FDA CS | M0020790 | Sulfonamides |
| FDA MoA | N0000000235 | Carbonic Anhydrase Inhibitors |
| FDA PE | N0000008486 | Decreased Central Nervous System Disorganized Electrical Activity |
| MeSH PA | D000927 | Anticonvulsants |
| MeSH PA | D002121 | Calcium Channel Blockers |
| MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
| CHEBI has role | CHEBI:22586 | antioxidants |
| CHEBI has role | CHEBI:35470 | central nervous system agents |
| CHEBI has role | CHEBI:35623 | anticonvulsants |
| CHEBI has role | CHEBI:50267 | protective agents |
| CHEBI has role | CHEBI:194338 | T-type calcium channel blockers |
| FDA EPC | N0000175753 | Anti-epileptic Agent |
| FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diffuse Lewy body disease | indication | 80098002 | |
| Partial Epilepsy Treatment Adjunct | indication | ||
| Suicidal thoughts | contraindication | 6471006 | |
| Agranulocytosis | contraindication | 17182001 | DOID:12987 |
| Mood swings | contraindication | 18963009 | |
| Depressive disorder | contraindication | 35489007 | |
| Metabolic acidosis | contraindication | 59455009 | |
| Diarrhea | contraindication | 62315008 | |
| Psychotic disorder | contraindication | 69322001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Kidney stone | contraindication | 95570007 | |
| Diminished sweating | contraindication | 111980002 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Aplastic anemia | contraindication | 306058006 | DOID:12449 |
| Severe chronic obstructive pulmonary disease | contraindication | 313299006 | |
| Fever | contraindication | 386661006 | |
| Surgical procedure | contraindication | 387713003 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.47 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 100MG/5ML | ZONISADE | AZURITY | N214273 | July 15, 2022 | RX | SUSPENSION | ORAL | 11478456 | Aug. 18, 2038 | A METHOD OF TREATING SEIZURES |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium channel protein type 1 subunit alpha | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL | |||||
| Carbonic anhydrase 2 | Enzyme | Ki | 6.99 | WOMBAT-PK | |||||
| Voltage-dependent T-type calcium channel subunit alpha-1G | Ion channel | WOMBAT-PK | |||||||
| Carbonic anhydrase 1 | Enzyme | Ki | 7.25 | WOMBAT-PK | |||||
| Carbonic anhydrase 4 | Enzyme | Ki | 5.07 | CHEMBL | |||||
| Amine oxidase [flavin-containing] B | Enzyme | Ki | 5.51 | CHEMBL | |||||
| Carbonic anhydrase 9 | Enzyme | Ki | 8.30 | WOMBAT-PK | |||||
| Carbonic anhydrase 12 | Enzyme | INHIBITOR | Ki | 4.96 | IUPHAR | ||||
| Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 7.70 | CHEMBL | |||||
| Carbonic anhydrase 5B, mitochondrial | Enzyme | Ki | 5.22 | CHEMBL | |||||
| Carbonic anhydrase 7 | Enzyme | Ki | 6.93 | CHEMBL | |||||
| Carbonic anhydrase 6 | Enzyme | Ki | 7.05 | CHEMBL | |||||
| Carbonic anhydrase 14 | Enzyme | Ki | 5.28 | CHEMBL | |||||
| Carbonic anhydrase 13 | Enzyme | Ki | 6.37 | CHEMBL | |||||
| Carbonic anhydrase V | Enzyme | Ki | 7.69 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 6.66 | CHEMBL | |||||
| Amine oxidase [flavin-containing] B | Enzyme | Ki | 5.54 | CHEMBL | |||||
| Carbonic anhydrase 15 | Enzyme | Ki | 6.20 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 6.97 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 7.46 | CHEMBL | |||||
| Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase | Enzyme | Ki | 6.68 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 6.94 | CHEMBL | |||||
| Alpha carbonic anhydrase | Enzyme | Ki | 6.59 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 6.19 | CHEMBL | |||||
| Carbonic anhydrase 2 | Enzyme | Ki | 6.01 | CHEMBL | |||||
| Astrosclerin-3 | Enzyme | Ki | 6.78 | CHEMBL | |||||
| Beta-carbonic anhydrase 1 | Enzyme | Ki | 4.54 | CHEMBL | |||||
| Delta carbonic anhydrase | Unclassified | Ki | 6.39 | CHEMBL | |||||
| Carbonic anhydrase 2 | Enzyme | Ki | 6.06 | CHEMBL | |||||
| Carbonic anhydrase 3 | Enzyme | Ki | 5.07 | CHEMBL | |||||
| Amine oxidase [flavin-containing] | Enzyme | Ki | 4.51 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 6.58 | CHEMBL | |||||
| Carbonic anhydrase, alpha family | Unclassified | Ki | 6.39 | CHEMBL | |||||
| Carbonate dehydratase | Enzyme | Ki | 6.85 | CHEMBL | |||||
| Amine oxidase [flavin-containing] B | Enzyme | IC50 | 4.61 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021224 | VUID |
| N0000148668 | NUI |
| D00538 | KEGG_DRUG |
| 4021224 | VANDF |
| C0078844 | UMLSCUI |
| CHEBI:10127 | CHEBI |
| ZON | PDB_CHEM_ID |
| CHEMBL750 | ChEMBL_ID |
| DB00909 | DRUGBANK_ID |
| D000078305 | MESH_DESCRIPTOR_UI |
| 5734 | PUBCHEM_CID |
| 7047 | IUPHAR_LIGAND_ID |
| 5575 | INN_ID |
| 459384H98V | UNII |
| 261708 | RXNORM |
| 31898 | MMSL |
| 73622 | MMSL |
| 8781 | MMSL |
| d04527 | MMSL |
| 008137 | NDDF |
| 125693002 | SNOMEDCT_US |
| 398762003 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8266 | CAPSULE | 100 mg | ORAL | ANDA | 23 sections |
| zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8266 | CAPSULE | 100 mg | ORAL | ANDA | 23 sections |
| ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-539 | CAPSULE | 100 mg | ORAL | ANDA | 16 sections |
| ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-724 | CAPSULE | 25 mg | ORAL | ANDA | 13 sections |
| ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-155 | CAPSULE | 100 mg | ORAL | ANDA | 28 sections |
| ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-654 | CAPSULE | 50 mg | ORAL | ANDA | 28 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-428 | CAPSULE | 25 mg | ORAL | ANDA | 12 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-428 | CAPSULE | 25 mg | ORAL | ANDA | 12 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-429 | CAPSULE | 50 mg | ORAL | ANDA | 12 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-429 | CAPSULE | 50 mg | ORAL | ANDA | 12 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-430 | CAPSULE | 100 mg | ORAL | ANDA | 12 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-430 | CAPSULE | 100 mg | ORAL | ANDA | 12 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-228 | CAPSULE | 100 mg | ORAL | ANDA | 25 sections |
| ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-843 | CAPSULE | 100 mg | ORAL | ANDA | 13 sections |
| ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35356-143 | CAPSULE | 100 mg | ORAL | ANDA | 16 sections |
| ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35356-143 | CAPSULE | 100 mg | ORAL | ANDA | 16 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-932 | CAPSULE | 25 mg | ORAL | ANDA | 22 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-816 | CAPSULE | 100 mg | ORAL | ANDA | 26 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-137 | CAPSULE | 25 mg | ORAL | ANDA | 22 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-137 | CAPSULE | 25 mg | ORAL | ANDA | 22 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-138 | CAPSULE | 50 mg | ORAL | ANDA | 22 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-138 | CAPSULE | 50 mg | ORAL | ANDA | 22 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-139 | CAPSULE | 100 mg | ORAL | ANDA | 22 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-139 | CAPSULE | 100 mg | ORAL | ANDA | 22 sections |
| ZONISADE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52652-8001 | SUSPENSION | 100 mg | ORAL | NDA | 30 sections |
| ZONISADE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52652-8001 | SUSPENSION | 100 mg | ORAL | NDA | 30 sections |
| zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53217-301 | CAPSULE | 100 mg | ORAL | ANDA | 24 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5789 | CAPSULE | 100 mg | ORAL | ANDA | 14 sections |
| Zonisamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6221 | CAPSULE | 50 mg | ORAL | ANDA | 14 sections |
| ZONISAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-945 | CAPSULE | 25 mg | ORAL | ANDA | 13 sections |